NCT03922776 2026-03-18
TILsOV
Centre Oscar Lambret
Phase NA Terminated
Clinical Trials
289 trialsNCT04016142 2026-03-18
ACCRAPAN
Centre Oscar Lambret
Phase 2 Terminated
NCT01641484 2026-03-13
ANOXICOL
Centre Oscar Lambret
Phase NA Terminated
NCT04651127 2026-03-10
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Sun Yat-sen University
Phase 1/2 Terminated
NCT05159050 2026-02-25
Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis
University of Iowa
Phase 1 Terminated
NCT04780945 2026-02-17
FAB
Leiden University Medical Center
Phase 2 Terminated
NCT05082025 2026-01-09
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01048853 2026-01-07
Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer
M.D. Anderson Cancer Center
Phase NA Terminated
NCT05458960 2025-12-26
BASICS
Washington University School of Medicine
Phase NA Terminated
NCT04000477 2025-12-23
ENDOCOL
University Hospital, Lille
Phase NA Terminated
NCT05769062 2025-10-15
Identification and Prevention of Pelvic Floor Dysfunction in Gynecologic Cancer Survivors
Washington University School of Medicine
Phase NA Terminated
NCT05263492 2025-10-02
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Virginia Commonwealth University
Phase 2 Terminated
NCT05036681 2025-09-17
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02554565 2025-09-08
PAIR HPV
Institut Curie
Phase NA Terminated
NCT00766142 2025-08-29
COCHISE
Institut Bergonié
Phase 2 Terminated
NCT05708924 2025-08-14
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT04159155 2025-08-12
CAN-STAMP
University Health Network, Toronto
Phase 2/3 Terminated
NCT04611126 2025-08-12
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Herlev Hospital
Phase 1/2 Terminated
NCT06086054 2025-08-05
Effect of a Childcare Resource on Cervical Cancer Prevention
University of Texas Southwestern Medical Center
Phase NA Terminated
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT04030429 2025-07-16
Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer
National Cheng-Kung University Hospital
Phase 2 Terminated
NCT02140021 2025-07-14
Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer
M.D. Anderson Cancer Center
Phase NA Terminated
NCT04116320 2025-07-14
AM-003
University of Virginia
Phase 1 Terminated
NCT02432378 2025-06-19
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT04527900 2025-06-19
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
University of Maryland, Baltimore
Phase 2 Terminated
NCT04503668 2025-06-18
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
University of Michigan Rogel Cancer Center
Phase 3 Terminated
NCT05029154 2025-06-12
Exercise Preconditioning in Ovarian Cancer
University of Virginia
Phase NA Terminated
NCT04019288 2025-06-11
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03277482 2025-05-31
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT03294694 2025-05-31
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT04861181 2025-05-22
NIRAPK
Hospices Civils de Lyon
Phase 4 Terminated
NCT05396794 2025-05-15
SCC-BAREDU
University of Oklahoma
Terminated
NCT03456700 2025-05-08
Auranofin and Sirolimus in Treating Participants With Ovarian Cancer
Mayo Clinic
Phase 2 Terminated
NCT02569957 2025-05-04
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT05462249 2025-04-30
HPVAC2
University Hospital, Brest
Terminated
NCT06106633 2025-04-24
PEDD-UFE
Massachusetts General Hospital
Phase NA Terminated
NCT04514692 2025-04-23
Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
Stanford University
Phase 1/2 Terminated
NCT04278326 2025-04-20
ORGANOIDES
Centre Hospitalier Régional d'Orléans
Phase NA Terminated
NCT03610490 2025-04-17
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03267680 2025-04-13
IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3
University of Southern California
Phase 2 Terminated
NCT05523440 2025-03-28
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
University of Oklahoma
Phase 2 Terminated
NCT03164980 2025-03-20
COMPASS
North Eastern German Society of Gynaecological Oncology
Phase 4 Terminated
NCT04421547 2025-03-07
MITO32
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Terminated
NCT04750941 2025-03-04
Study of Copanlisib and Ketogenic Diet
Columbia University
Phase 2 Terminated
NCT04213794 2025-02-20
TOASTIT
Mayo Clinic
Phase EARLY_PHASE1 Terminated
NCT04906382 2025-02-13
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT03891576 2025-01-17
Newton
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT04072406 2024-12-30
A Self-Directed Mindfulness Meditation Intervention in Gynecologic Cancer Patients
Washington University School of Medicine
Phase NA Terminated
NCT06752135 2024-12-30
HRCC1
Azienda Policlinico Umberto I
Terminated
NCT03099499 2024-12-24
Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
Fox Chase Cancer Center
Phase 2 Terminated